Corporate ActionMay 26, 2026, 09:08 AM
Editas Medicine Prices $125M Public Offering of Stock and Warrants
AI Summary
Editas Medicine announced the pricing of an underwritten public offering of 55,555,556 shares of its common stock and accompanying common stock warrants. Each share and warrant are being sold together at a combined public offering price of $2.25, expecting to generate approximately $125.0 million in gross proceeds. If all common stock warrants are exercised at $3.50 per share, the Company would receive an additional $194.4 million. The warrants' expiry is tied to Phase 1 clinical data for EDIT-401 or three years from issuance.
Key Highlights
- Priced underwritten public offering of 55,555,556 shares and 55,555,556 warrants.
- Combined public offering price of $2.25 per share and accompanying warrant.
- Expected gross proceeds of approximately $125.0 million from the offering.
- Potential additional gross proceeds of approximately $194.4 million if all warrants are exercised.
- Common stock warrants have an exercise price of $3.50 per share.
- Warrants expire based on EDIT-401 Phase 1 clinical data or three years from issuance.
- Offering expected to close on or about May 27, 2026.
Price Impact
More from EDIT